Canagliflozin mediates tumor suppression alone and in combination with radiotherapy in non‐small cell lung cancer (NSCLC) through inhibition of HIF‐1α

Canagliflozin mediates tumor suppression alone and in combination with radiotherapy in non‐small cell lung cancer (NSCLC) through inhibition of HIF‐1α

Non‐small cell lung cancer (NSCLC) has a poor prognosis, and effective therapeutic strategies are lacking. The diabetes drug canagliflozin inhibits NSCLC cell proliferation and the mammalian target of rapamycin (mTOR) pathway, which mediates cell growth and survival, but it is unclear whether this d...

Full description

Bibliographic Details
Main Authors: Olga‐Demetra Biziotis, Evangelia Evelyn Tsakiridis, Amr Ali, Elham Ahmadi, Jianhan Wu, Simon Wang, Bassem Mekhaeil, Kanwaldeep Singh, Gabe Menjolian, Thomas Farrell, Bassam Abdulkarim, Ranjan K. Sur, Aruz Mesci, Peter Ellis, Tobias Berg, Jonathan L Bramson, Paola Muti, Gregory R Steinberg, Theodoros Tsakiridis
Format: Article
Language:English
Published: Wiley 2023-11-01
Series:Molecular Oncology
Subjects:
canagliflozin
HIF‐1α
lung cancer
mTOR
radiotherapy
Online Access:https://doi.org/10.1002/1878-0261.13508

Internet

https://doi.org/10.1002/1878-0261.13508

Similar Items